These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 33833387)

  • 1. Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape.
    Hsieh YC; Kirschner K; Copland M
    Leukemia; 2021 May; 35(5):1229-1242. PubMed ID: 33833387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment-free remission and immunity in chronic myeloid leukemia.
    Ureshino H
    Int J Hematol; 2021 May; 113(5):642-647. PubMed ID: 33651270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.
    Hughes A; Clarson J; Tang C; Vidovic L; White DL; Hughes TP; Yong AS
    Blood; 2017 Mar; 129(9):1166-1176. PubMed ID: 28049640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.
    Hughes A; Yong ASM
    Front Immunol; 2017; 8():469. PubMed ID: 28484463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of cancer immunology in chronic myelogenous leukemia.
    Ureshino H; Shindo T; Kimura S
    Leuk Res; 2020 Jan; 88():106273. PubMed ID: 31765938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allelic polymorphisms of
    Shindo T; Ureshino H; Kojima H; Tanaka H; Kimura S
    Immunol Med; 2021 Jun; 44(2):61-68. PubMed ID: 32715973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells.
    Irani YD; Hughes A; Clarson J; Kok CH; Shanmuganathan N; White DL; Yeung DT; Ross DM; Hughes TP; Yong ASM
    Br J Haematol; 2020 Nov; 191(3):433-441. PubMed ID: 32352166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
    Cayssials E; Torregrosa-Diaz J; Gallego-Hernanz P; Tartarin F; Systchenko T; Maillard N; Desmier D; Machet A; Fleck E; Corby A; Motard C; Denis G; Herbelin A; Gombert JM; Roy L; Ragot S; Leleu X; Guilhot F; Chomel JC
    Cancer; 2020 Aug; 126(15):3438-3447. PubMed ID: 32459375
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Ureshino H; Shindo T; Tanaka H; Saji H; Kimura S
    Mol Cancer Ther; 2021 Jan; 20(1):142-149. PubMed ID: 33082274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tyrosine kinase inhibitor therapy discontinuation for chronic myelogenous leukemia to achieve clinical cure: current status and future perspectives].
    Kumagai T
    Rinsho Ketsueki; 2018; 59(10):2094-2103. PubMed ID: 30305514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chronic myeloid leukemia and NK cell immunity].
    Ureshino H; Shindo T; Tanaka H; Kimura S
    Rinsho Ketsueki; 2017; 58(4):381-388. PubMed ID: 28484170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment.
    Kong J; Qin YZ; Zhao XS; Hou Y; Liu KY; Huang XJ; Jiang H
    Ann Hematol; 2021 Oct; 100(10):2557-2566. PubMed ID: 34278524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia.
    Irani YD; Kok CH; Clarson J; Shanmuganathan N; Branford S; Yeung DT; Ross DM; Hughes TP; Yong ASM
    Blood Adv; 2023 Jun; 7(11):2364-2374. PubMed ID: 36622326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic role of NKG2A expression for patients with chronic myeloid leukemia after treatment discontinuation.
    Xu Z; Yin J; Sun Q; Hu J; Hong M; Qian S; Liu W
    Leuk Lymphoma; 2022 Nov; 63(11):2616-2626. PubMed ID: 35758278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
    Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid Leukemia.
    Inselmann S; Wang Y; Saussele S; Fritz L; Schütz C; Huber M; Liebler S; Ernst T; Cai D; Botschek S; Brendel C; Calogero RA; Pavlinic D; Benes V; Liu ET; Neubauer A; Hochhaus A; Burchert A
    Cancer Res; 2018 Nov; 78(21):6223-6234. PubMed ID: 30166420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TKI discontinuation in CML: how do we make more patients eligible? How do we increase the chances of a successful treatment-free remission?
    Hochhaus A; Ernst T
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):106-112. PubMed ID: 34889388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis the influence factors of treatment free remission outcome with chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitors].
    Zhao HF; Zhang Y; Dang LX; Liang JL; Chen SX; Guo Z; Li YL; Zu RR; Gui XD; Wei YP; Song Y
    Zhonghua Yi Xue Za Zhi; 2022 May; 102(20):1523-1529. PubMed ID: 35692068
    [No Abstract]   [Full Text] [Related]  

  • 19. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.
    Bernardi S; Malagola M; Zanaglio C; Polverelli N; Dereli Eke E; D'Adda M; Farina M; Bucelli C; Scaffidi L; Toffoletti E; Deambrogi C; Stagno F; Bergamaschi M; Franceschini L; Abruzzese E; Divona MD; Gobbi M; Di Raimondo F; Gaidano G; Tiribelli M; Bonifacio M; Cattaneo C; Iurlo A; Russo D
    Cancer Med; 2019 May; 8(5):2041-2055. PubMed ID: 30950237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells.
    Cayssials E; Jacomet F; Piccirilli N; Lefèvre L; Roy L; Guilhot F; Chomel JC; Leleu X; Gombert JM; Herbelin A; Barbarin A
    Br J Haematol; 2019 Jul; 186(1):54-59. PubMed ID: 30864168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.